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Abstract 
Blood brain barrier (BBB) breakdown and neuroinflammation are key events in ischemic 
stroke morbidity and mortality.  The present study investigated the effects of mast cell 
deficiency and stabilisation on BBB breakdown and neutrophil infiltration in mice after 
transient middle cerebral artery occlusion (tMCAo).  Adult male C57BL6/J (wild type (WT)) 
and mast cell deficient (C57BL6/J Kit 
Wsh/Wsh
 (Wsh)) mice underwent tMCAo and BBB 
breakdown, brain edema and neutrophil infiltration were examined after 4 hours of 
reperfusion. 
BBB breakdown, brain edema and neutrophil infiltration were significantly reduced in Wsh 
versus WT mice (<0.05).  These results were reproduced pharmacologically using mast cell 
stabiliser, cromoglycate.  WT mice administered cromoglycate intraventricularly exhibited 
reduced BBB breakdown, brain edema and neutrophil infiltration versus vehicle (<0.05).  
There was no effect of cromoglycate versus vehicle in Wsh mice, validating specificity of 
cromoglycate on brain mast cells.  Proteomic analysis in Wsh versus WT indicated that 
effects may be via expression of endoglin, endothelin11 and matrix metalloproteinase19.   
Using an 	 model of mast cell deficiency, this is the first study showing that mast cells 
promote BBB breakdown in focal ischemia in mice, and opens up future opportunities for 
using mice to identify specific mechanisms of mast cell1related BBB injury. 
Keywords: Blood brain barrier, Brain edema, Focal Ischemia, Inflammation, Reperfusion 
 
 
 
 
Introduction 
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Ischemic stroke contributes significantly to morbidity and mortality in the ageing population 
and despite many years of promising research there remains a paucity of treatment options 
available.
1
 
Therefore, identifying novel therapeutic targets, by improving our understanding of the 
progression of injury, is of paramount importance.
2
 Early damaging events of the ischemic 
cascade including blood brain barrier (BBB) hyperpermeability, vasogenic edema and onset 
of inflammation are important in determining survival and recovery of individuals suffering 
stroke.
3
 Recent evidence from human 
4,5
 and animal 
6,7
 studies suggest that mast cells may be 
important in determining stroke severity. 
Mast cells, derived from hematopoietic lineage, are involved in a number of normal 
physiological functions such as immunity,
8
 angiogenesis and tissue remodelling,
9
 as well as 
being implicated in multiple pathological processes.
10
 To exert these effects, mast cells store 
and release upon activation granules containing pre1formed histamine, serotonin, heparin, 
neutral proteases, major basic protein, acid hydrolases, peroxidase, phospholipases and 
tumour necrosis factor alpha (TNF1α), among others.  Additionally, mast cells synthesise 	
 various pro1inflammatory cytokines, chemokines, lipid mediators and growth factors.
11
 
Mast cells are resident in the brain, located on or near the cerebrovasculature particularly 
within the dura,
12 
on the brain side of the BBB, with a high percentage of mast cells in 
contact with astrocytic end1feet.
13
 Therefore, given the mast cell1derived mediators and their 
perivascular location, upon degranulation at the onset of ischemia, mast cells have a potential 
role in the initiation of the early phase of ischemic damage.
14
   
Increased mast cell degranulation was evident after stroke in the immature brain,
15
 and after 
transient global ischemia in the adult rat
16
 as well as after oxygen glucose deprivation 	
,
17
 implying a role for mast cells in neuronal injury.  In addition mast cell numbers 
increased within 2 hours of hypoxia ischemia in rat pups.
18
 The increase in mast cell numbers 
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was prior to neuronal apoptosis or activation of astrocytes and microglia, indicating a very 
early role for mast cells.
18
 
A number of mediators released by mast cells may play a role in stroke.  Of particular interest 
is TNF1α as it comprises 25% of mast cell granule content, and a number of studies have 
highlighted the role of this cytokine in stroke. For example, TNF1α is thought to be key to 
enhancing BBB permeability and inhibition of TNF1α significantly reduced infarct size in 
mice after transient middle cerebral artery occlusion (tMCAo).
19,20
 The percentage of TNF1α1
containing mast cells has been shown to increase dramatically, ipsilaterally immediately after 
hypoxia1ischemia in rat pups
21 
and mast cell1derived TNF1α has been shown to increase T 
cell infiltration, proliferation, function and cytokine production,
22
 which may contribute to 
ischemic damage. 
Previous 	  studies in a rat model of ischemic stroke indicated that mast cells are 
important regulators of the acute ischemic response.
6, 7
 Genetically mast cell deficient rats 
and those treated with the mast cell stabilising agent cromoglycate prior to ischemia had 
significant reductions in BBB permeability, brain edema and neutrophil recruitment four 
hours post ischemia.  Additionally, rats pre1treated with the mast cell secretatouge 48/80 had 
elevated BBB permeability and brain edema.
6
 Furthermore, cromoglycate administration to 
Wistar rats thirty minutes prior to exposure to a hypoxic gas mixture for a period of ninety 
minutes significantly reduced neuronal cell death and reduced the activation of astrocytes and 
microglia through stabilisation of mast cells.
18 
  
Whereas previous studies of mast cells in MCAo have used rats; this is the first study that 
investigates whether mast cells promote BBB breakdown and neutrophil infiltration after 
focal cerebral ischemia in mice using an 	  model of mast cell deficiency.  This will 
allow, in future, a more mechanistic insight into the specific mediators of BBB breakdown by 
reconstituting mast cell deficient mice with bone marrow1derived cultured mast cells 
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(BMMC) from genetically modified mice deficient in specific mast cell mediators such as 
MMP19 or TNF1α. 
Here we test the hypothesis that mast cells and their secreted mediators potentiate BBB 
damage, vasogenic edema and inflammation in the acute post1ischemic phase in a mouse 
model of stroke.  We report on the function of mast cells in tMCAo, and reveal some of the 
mechanisms by which they may be exerting their effect 	 in the acute response to stroke 
and assess their contribution to subacute recovery. 
Materials and Methods 
Induction of Ischemia 
The regulations, as specified by the Animals (Scientific Procedures) Act (1986), were strictly 
adhered to throughout and were carried out under ethical approval of University of 
Strathclyde and the appropriate Home Office licence (Project Licence No. PPL 60/3775; 
Personal licence 60/11900).  All procedures were carried out in accordance with ARRIVE
23 
and STAIR
24
 guidelines where possible. All experiments were carried out on adult male 
C57BL/6 wild type (WT, n=53) or C57BL6/J Kit 
Wsh/Wsh
 (Wsh, n=52) mice. All efforts were 
made to minimize animal suffering and the number of animals used, n=518/group, based on 
power calculations at 80% power and significance level of 5%.
25
 WT mice were either bred 
in1house or purchased from Charles River Laboratories. Wsh mice were originally sourced 
from Jackson Laboratories, USA and the colony maintained in1house. The Wsh mutant first 
arose around 30 years ago by spontaneous mutation of the transcription regulatory elements 
of the start site of c1kit transcription, a cell surface receptor for stem cell factor vital for mast 
cell maturation and survival.
11,26
 This mutation was then backcrossed to the WT background 
through ten generations. Wsh mice have white coat while WT mice have dark coat preventing 
allocation concealment and blinding during assessment of neurological outcome (Clarks 
score) for WT versus Wsh studies. Prior to surgery, animals were housed in their home cage 
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in a temperature controlled environment, with a 12 hour light dark cycle and were given 
access to food and water 	.   
Male WT or Wsh mice aged 10112 weeks and weighing 25130g were anaesthetised by 
inhalation of 3% isoflurane/1000ml/min oxygen (O2) and maintained between 1.5% to 2% 
isoflurane/1000ml/min O2 for the remainder of the procedure.  Body temperature was 
monitored using a rectal probe and maintained at 37 ± 0.5 ˚C with an automatic heat mat 
(Harvard Apparatus, Kent, Edenbridge, UK). Perfusion of the MCA territory was measured 
in some animals throughout the surgical procedure using a laser Doppler flowmeter (Moor 
Instruments, Axminster, UK).  Using Bregma as a reference point, the probe was glued in 
place approximately anterior/posterior 11mm, medial/lateral +2.5mm and readings were 
recorded at five minute intervals throughout the procedure. 
Transient middle cerebral artery occlusion (tMCAo) was performed by adaptation of the 
Longa method for mice.
27
 A monofilament (20 mm length of which 9 mm is coated with 
silicone giving an overall diameter of 0.23 +/1 0.01 mm) (Doccol Corporation, Sharon, USA) 
was inserted into the left external carotid artery and advanced along the internal carotid artery 
until resistance was met at the origin of the MCA.  At this point the filament was tied in place 
and remained for 20 minutes for TNF1α study or 45 minutes for all other animals before 
being withdrawn to allow reperfusion.  The 20 minute occlusion animals were recovered for 
5 minutes (time after occlusion onset 25 minutes), whilst the 45 minute occlusion animals 
recovered for 45 minutes (time after occlusion onset 90 minutes), 4 hours or 72 hours. For 
animals undergoing sham operation, all procedures were followed as described, however the 
filament was removed immediately after insertion. A priori exclusion criteria were any 
animal found to be moribund due to excessive weight loss (>20% of start weight) or that 
exhibited no ischemic injury. To establish severity of deficit, animals recovering to 72 hours 
were assessed for development of general (e.g. posture, spontaneous activity) and focal (e.g. 
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circling) neurological deficits using the Clarks deficit scoring system at 24, 48 and 72 hours 
post1tMCAo, where scores for both range from 0 (healthy) to 28.
28
 
Stereotaxic Injection of Cromoglycate 
In one set of experiments, WT and Wsh mice were randomly assigned to receive either 
cromoglycate (Sigma, Poole, UK) (75Mg in 2Ml saline) or sterile saline (vehicle), injected into 
the ventricle, anterior/posterior 10.6mm medial/lateral, +1mm, relative to Bregma and 2.4mm 
ventral, using the surface of the dura for zero reference. Stereotaxic injection was performed 
immediately prior to onset of MCAo under the same anesthesia using a 32 gauge needle 
attached to a Hamilton syringe. Blinding of vehicle/cromoglycate assignment prior to stroke 
induction was achieved by independent investigator. Over a two minute period 2Ml of sodium 
cromoglycate or vehicle was injected, and the needle was left in place for a further two 
minutes.  The needle was then slowly retracted and the wound sutured. 
Termination and Tissue Processing 
The experimenter was blinded to the experimental group to which the animal belongs (mouse 
genotype, treatment received, stroke or sham surgery received) in all post1mortem analysis by 
recoding of animals by an independent investigator. At the end of each experiment animals 
were killed by injection of 200Ml of sodium pentobarbital.  The brains were then immediately 
removed and either fresh frozen in isopentane (140˚C) for histology or the hemispheres 
separated and homogenised in 1% protease inhibitor (in 20mM TRIS, pH 7.4) at a 5 times 
w/v ratio, and kept on ice.  Triton X1100 was added to samples to a concentration of 1% and 
aliquots were stored at 180˚C.  Prior to use, samples were centrifuged at 2000g for ten 
minutes and the supernatant removed for analysis.   
Histological Processing  
Hematoxylin and eosin1stained 20 Mm thick coronal sections from eight distinct 
neuroanatomical regions representative of the forebrain
29
 were analysed for measurement of 
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lesion and brain edema using a densitometer. For each section, the ipsilateral and 
contralateral hemispheric areas were measured, as well as areas of ischemic lesion 
represented by regions of pallor.  For confirmation, ischemic damage was assessed under a 
light microscope through identification of regions containing pyknotic and necrotic neurons.  
The volumes of each hemisphere and of the lesion were calculated from area under the curve 
of areas measured at each of the eight coronal levels against their interaural (IA) distance, 
where Y intersected X at 7.9 mm IA and 0.1 mm IA respectively.  Brain edema volume was 
expressed as a percentage increase in the ipsilateral hemisphere over the contralateral volume 
as follows: (ipsilateral hemisphere volume 1 contralateral hemisphere volume)/contralateral 
hemisphere volume x 100. 
Toluidine blue metachromasia was used to identify mast cells in tissue.  For each animal a 
total of  24 coronal, 4% paraformaldehyde1fixed sections were stained, two from each of the 
eight regions of the forebrain, with additional sections from regions 2.86 mm, 1.98 mm, 1.00 
mm and 0.16 mm interaural, due to a previous observation that mast cell numbers were 
higher in the posterior regions of the forebrain (unpublished observation).  Cells were 
manually counted under a light microscope (x200 magnification). 
Assessment of BBB Permeability 
Permeability of the BBB was measured by labelling endogenous immunoglobulin G (IgG) 
within brain tissue, which would normally be excluded by an intact BBB.
30
 Coronal acetone1
fixed sections at regions of the MCA territory, at the level of the septal nucleus (3.94mm IA) 
and at the level of the hypothalamus (2.86mm IA), were stained with either FITC1conjugated 
goat anti1mouse IgG (prepared in 5% normal goat serum) (1:250) (Abcam Ltd, UK), or 
FITC1conjugated horse anti1mouse IgG (1:250) (Abcam Ltd, Cambridge, UK) and 
Vectashield
®
 (Vector Laboratories, Peterborough, UK), containing the nuclear stain 4',61
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diamidino121phenylindole (DAPI).  Negative controls were incubated in the absence of 
antibody. 
Stained sections were analysed using an upright epifluorescent microscope (Nikon Eclipse 
E600) at 200x magnification, at excitation wavelengths of 405 nm and 488 nm for DAPI and 
FITC respectively along with Metamorph imaging software. A fluorescent threshold was set 
by reduction of the exposure time of the negative controls until no signal was detected. 
Thereafter, images were acquired of fluorescently1stained tissue within the ipsilateral 
hemisphere.  Using Image J software, areas and density of FITC fluorescence were measured.   
Neutrophil Quantification 
Immunofluorescent staining was performed to identify and quantify neutrophil infiltration 
post1tMCAo in adjacent sections to BBB measurements at the level of the septal nucleus 
(3.94mm IA) as well as at the level of the anterior hippocampus (1.98mm IA).  Neutrophils 
were labelled using SJC, a custom rabbit polyclonal antibody (1:1000 dilution) (Gifted by 
Daniel Anthony, University of Oxford, UK), and secondary FITC1conjugated goat anti1rabbit 
(1:250) with cell nuclei stained using Vectashield
®
. Neutrophil infiltration was identified and 
quantified using an upright epifluorescent microscope (Nikon Eclipse E600), at excitation 
wavelengths of 405 nm and 488 nm for DAPI and FITC respectively.  Cells fluorescently 
marked in both hemispheres were quantified in duplicate sections and the mean number of 
cells expressed.     
Enzyme Linked Immunosorbent Assay 
The concentration of TNF1α was measured in brain homogenates using a commercially 
available set, Mouse TNF1α set 1 (BD Biosciences, Oxford, UK).  Brains from mice which 
underwent tMCAo of 20 minutes and 45 minutes followed by 5 minutes and 45 minutes 
reperfusion respectively were removed upon termination.  Brains were placed in 1% protease 
inhibitor (in 20mM TRIS, pH 7.4) (Merck Chemicals, Nottingham, UK), at a 5 times w/v 
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ratio, and kept on ice.  The hemispheres were separated and homogenised with a hand held 
homogeniser until the sample was cloudy and contained no visible pieces of tissue.  Triton X1
100 (Sigma, Poole, UK) was added to samples to a concentration of 1% and aliquots were 
stored at 170˚C.  Prior to use, samples were centrifuged at 2000g for ten minutes and the 
supernatant removed for analysis. The assay was carried out according to the manufacturers’ 
guidelines.  Samples (1/5 dilution) were prepared in assay diluent, were transferred to wells 
in triplicate.  The TNF1α concentration of each sample was determined from the absorbance 
values of TNF1α standards at 450 nm, using linear regression, R
2
=0.99. 
Protein Concentration Assay 
Protein concentration in brain homogenates was determined using the Bio1Rad Protein assay 
(Bio1Rad Laboratories, Hemel Hempstead, UK) using the same samples as above following 
manufacturer’s guidelines.  Samples were diluted 1:100 with dye reagent and the absorbance 
of each sample then read at 595nm. The protein concentration of each sample was determined 
from the absorbance values of the protein standards, using linear regression, R
2
=0.97. 
Mouse Angiogenesis Proteome Profiler 
Relative expression of an array of proteins associated with angiogenesis was measured in 
brain tissue homogenates, using the same samples as above, using a commercially available 
proteome profiler kit ARY015 (R&D Systems, Abingdon, UK).   
The protocol was carried out following the manufacturer’s guidelines.  Samples containing 
detection antibodies were incubated on a membrane permeated with capture antibodies.  
Array membranes were then placed in an autoradiography cassette and exposed to x1ray film 
for multiple periods between 1110 minutes.  5 minute exposure time was used for analysis 
due to uniformity of positive control. 
2.5 Statistics 
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Data are presented as mean + standard error of mean (S.E.M.). Comparisons between two 
groups were carried out using Students’ unpaired t1test. Cerebral blood flow (CBF) 
measurements were analysed using two1way analysis of variance (ANOVA). Comparisons 
among multiple groups were analysed by one1way ANOVA with Bonferroni correction. 
P<0.05 was considered significant throughout. 
Results 
CBF and Neurological Deficit were Unaffected by Mast Cell Deficiency 
Given the potential vasoactive effects of mast cell1derived mediators and potential vascular 
differences between the two strains of mice used, we monitored CBF within the MCA 
territory throughout the occlusion period by laser Doppler flowmetry in WT and Wsh mice.  
However, we found that blood flow was reduced to a similar level in both WT and Wsh mice
 
during the occlusion (Figure 1A).  Following placement of the microvascular clip on the left 
internal carotid artery, blood flow dropped to around 60% of baseline levels.  Perfusion was 
further decreased upon insertion of the filament, to 45% of baseline flow, where it remained 
stable throughout the occlusion period.  Removal of the intraluminal thread restored blood 
flow to a level similar to that prior to insertion.  This data would suggest that mast cells do 
not have an effect on local CBF during the ischemic period, and also suggest that Wsh mice 
have no inherent abnormalities that increase severity of ischemia. 
There were no animals excluded from either group due to excessive weight loss, according to 
the above1mentioned exclusion criteria. However there were 2 premature deaths in the WT 
group, while no mice died in the Wsh group.  The 2 deaths in the WT group occurred during 
the first 24 hours and were attributed to severe brain edema after ruling out hemorrhagic 
transformation and on observation of an enlarged ipsilateral hemisphere. In addition, 3 mice 
were excluded (WT (n=2) and Wsh (n=1)) due to absence of injury. The contribution of mast 
cells to neurological deficit was assessed at three time points post MCAo and there were no 
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significant differences in focal or general deficits between WT and Wsh mice at each time 
point (Figure 1B and 1C).   
Mast Cells Increased in the Ischemic Hemisphere in WT mice. 
The population of mast cells is known to increase in a number of disease states, which is 
indicative of active mast cell involvement in disease progression.
11
 Therefore, toluidine blue1
positive mast cells were counted in brains 4 hours post1tMCAo.  Mast cells were present 
within brains 4 hours post1tMCAo and in sham and naïve WT animals, located predominantly 
perivascularly within the posterior regions of the forebrain (Figure 2A and 2B). There were 
no mast cells observed in Wsh mice brains and there was no difference in mast cell numbers 
between the two hemispheres in the sham and naïve WT animals (Figure 2D).  Whereas the 
total brain numbers of mast cells after tMCAo did not change compared to sham (Figure 2C), 
mast cell numbers were increased by around 50% in the ipsilateral compared to the 
contralateral hemisphere after tMCAo in WT mice (<0.05, Figure 2D), indicating a 
potential  involvement of mast cells in this model of stroke.  
BBB Permeability was Reduced by Mast Cell Stabilisation and Deficiency.  
Mast cells have been shown previously to increase BBB permeability post1MCAo in a rat 
model.
6
 Therefore we measured endogenous IgG within brain tissue, which would be 
excluded from entering brain tissue by a healthy BBB. At 4 hours post1tMCAo, cromoglycate 
treatment significantly reduced IgG within the tissue compared to vehicle treatment in WT 
mice at the level of the hypothalamus (<0.05).  To confirm the specificity of the effects of 
cromoglycate on mast cells we repeated the experiments in Wsh mice and this reduction in 
IgG was not evident in cromoglycate1treated Wsh mice versus vehicle1treated Wsh mice 
(Figure 3A).  In a separate study comparing WT vs Wsh mice, intensity of staining of IgG 
was significantly reduced by more than 50% in Wsh mice compared to WT mice, at the 
coronal level of the hypothalamus at 4 hours post1tMCAo (<0.05) (Figure 3B) but not at 72 
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hours post1tMCAo (Figure 3C), or at the level of the septal nuclei at either time point (data 
not shown).  These results reflect the posterior localisation of mast cells illustrated in Figure 
2E and indicate that mast cells may have a detrimental effect on the BBB post MCAo, 
causing an increase in permeability to large molecules. 
Brain Edema Volume was Reduced by Mast Cell Stabilisation and Deficiency 
Mast cells have been shown to contribute to post1MCAo brain edema,
6 
and consistent with 
this, edema volume was significantly reduced by ~60% following cromoglycate treatment 
compared to vehicle in WT mice (<0.05) (Figure 4A). This reduction by cromoglycate 
compared to vehicle was not evident in Wsh mice. Swelling of the ipsilateral hemisphere was 
reduced by around 50% in the Wsh mice compared to the WT group at 4 hours post1tMCAo 
in this study (<0.05) (Figure 4B), but not at 72 hours post1tMCAo (Figure 4C).  These 
results clearly show that mast cells contribute to brain swelling post1 MCAo. 
Neutrophil Recruitment was Attenuated by Mast cell Stabilisation/Deficiency 
Neutrophils are known to contribute to post stroke injury through release of neurotoxic 
proteases and neutrophil elastase, and mast cells have been shown to be involved in their 
recruitment in the rat.
6 
Cromoglycate treatment significantly decreased neutrophil recruitment 
compared to vehicle treatment at the level of the septal nuclei in WT mice (<0.01) and had 
no effect on recruitment in Wsh mice (Figure 5A). In a separate study, neutrophil recruitment 
was significantly decreased in the Wsh mice compared to the WT mice 4 hours after tMCAo 
at the level of the septal nuclei (Figure 5B). Wsh mice had ~60% fewer neutrophils than WT 
mice (<0.05) and had similar numbers to both sham groups. No difference was found 
between groups at the region of the anterior hippocampus (data not shown).  These results are 
evidence that mast cells are involved in the recruitment of neutrophils to the brain post1
MCAo. 
Lesion Volume was Reduced by Mast Cell Stabilisation in WT Mice. 
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To assess the contribution of mast cells to the development of the ischemic lesion, volume of 
injury was assessed on tissue sections at termination of the experiment.  Lesion volume was 
significantly reduced by around 50% in WT mice pre1treated with cromoglycate versus 
vehicle at 4 hours post1tMCAo (<0.05) (Figure 6A).  Reduced lesion volume was not 
evident in Wsh mice administered cromoglycate compared to vehicle (Figure 6A).  In a 
separate series of experiments, lesion volume was measured in WT and Wsh mice 4 hours 
and 72 hours after onset of reperfusion.  There were no significant differences in the volume 
of lesion between the WT and Wsh mouse strains at either the 4 hour or 72 hour time point 
(Figure 6B and 6C).  There was no development of lesions in the sham1operated animals.  
These results show that mast cell stabilisation using cromoglycate contributes to attenuation 
of lesion development. 
TNF2α Levels in Brain tissue 
A wealth of evidence indicates TNF1α to both increase ischemic injury and to protect the 
brain from injury under certain conditions in animal models of stroke, and that it is expressed 
in the acutely injured ischemic brain.
19,20 
Mast cells are known to store pre1formed TNF1α,
21
 
and may be an early source of this cytokine.  Tissue concentrations of TNF1α, measured by 
ELISA, were similar in WT and Wsh
 
mice at 25 minutes post1onset of occlusion (20 minutes 
of occlusion, 5 minutes of reperfusion) or in sham animals (Figure 7A).  Likewise, the TNF1α 
concentration was similar in all WT and Wsh groups at 90 minutes post1onset of occlusion 
(45 minutes of occlusion, 45 minutes of reperfusion) (Figure 7B).   No TNF1α was detectable 
in serum samples at either time point analysed (data not shown).  This data does not support 
the idea that mast cells release a significant amount of TNF1α in the acute period post1MCAo 
measured in this study. 
Angiogenesis Array of Brain Tissue 
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Mast cells store and release upon stimulation a broad array of vasoactive and pro1angiogenic 
mediators
11
 which may be deleterious in the ischemic brain. Therefore we assessed the 
contribution of mast cells to the expression of 53 proteins known to be expressed by mast 
cells.  At 90 minutes post1onset of ischemia the proteomic profiles between WT and Wsh 
mice were strikingly different for three mediators. Despite expression in WT, there was a 
complete deficiency of expression of endoglin, endothelin11 and MMP19 in Wsh (Figure 7C), 
highlighting a potential role of mast cells in the expression of these mediators post1tMCAo. 
This result was reproduced in another set of WT and Wsh mice. In WT, endoglin was 
expressed with levels around 30140% of the positive control spot, whilst MMP19 expression 
was 20140% of the positive control spot and endothelin11 expression was approximately 18% 
of the control spot (Figure 7D). 
Discussion 
Being resident in the brain, in perivascular locations, and already present at onset of 
ischemia, mast cells are likely early initiators of neuroinflammation and BBB failure in 
stroke. The key findings of the present study are that mast cells increase in numbers in the 
ischemic hemisphere and promote neutrophil infiltration, BBB breakdown and edema within 
4 hours, but not by 72 hours, after transient MCAO in mice. These mast cell1mediated effects 
are not likely to be due to mast cell1derived TNF1alpha but possibly caused by MC1derived 
endothelin, endoglin and MMP19. 
In a previous study, mast cells were shown to increase after hypoxia1ischemia in the 
immature brain
18 
but in the present study, although the total number of mast cells in the brain 
does not change, this is the first time mast cells have been shown to increase in localisation in 
the ischemic hemisphere after tMCAo in adult mice. In addition mast cells stabilisation has 
been shown to reduce BBB breakdown and brain edema after tMCAo in the adult rat though 
no inflammatory response was assessed. We now extend these studies showing success of an 
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	 mouse model of mast cell deficiency after tMCAo and open up new opportunities for 
subsequent research into mechanistic insight of these cells after stroke. 
We have addressed our hypothesis using two strategies, namely an 	 model genetically 
deficient in mast cells (Wsh mice) and pharmacological stabilisation of mast cells 
(cromoglycate).  Wsh mice exhibit splenomegaly, cardiomegaly, and thrombocytosis, and are 
neutrophilic
31
 albeit such complications would be expected to exacerbate and not reduce 
stroke pathology. In addition lack of difference between WT and Wsh in severity of ischemia 
as measured by laser Doppler indicates no underlying cererbrovascular complications in Wsh 
mice. Our results were reproduced by pharmacological mast cell stabilisation in the WT mice 
but not in Wsh mice. Therefore we are confident that the strain differences observed in the 
present study are due to the specific Wsh mutation. The mechanism of cromoglycate in mast 
cell stabilisation is unclear; however, selectivity of effect on mast cells in WT mice is 
confirmed in the present study by lack of efficacy of cromoglycate in Wsh mice.  In addition, 
the central administration of cromoglycate would imply that the observed effect of 
cromoglycate is largely on brain mast cells rather than peripheral.  Taken together our results 
strongly indicate a role of mast cells in promoting neutrophil infiltration, BBB breakdown 
and brain edema in mice after stroke. 
Mast cells contain and release upon activation an array of mediators which can potentially 
decrease the integrity of the BBB leading to vasogenic edema, through degradation of ECM 
and tight junction proteins, such as MMP19.
7
 In the present study, we observed a lack of 
expression of MMP19 in Wsh mice observed at 90 minutes post1onset of ischemia. MMP19 is 
capable of digesting most of the ECM components including laminin, fibronectin, vitronectin 
and collagen, and also the tight junction proteins occludin and claudin.  Additionally, mast 
cell1derived chymase, tryptase and cathepsin G activate MMP19, from its inactive form, and 
also directly degrade the BBB independent of MMP19.
16
 Alternatively, mast cells may 
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promote neutrophil infiltration, as shown in the present study, a potent source of MMP19.
32
 
Therefore, the deficiency in expression of MMP19 in the Wsh compared to WT mice 
indicates a potential direct or indirect mast cell contribution to BBB degradation in focal 
cerebral ischemia. 
Deficiencies in endothelin11 and endoglin expression were also revealed in Wsh compared to 
WT mice after focal ischemia.  In both experimental and human stroke, the vasoconstrictor 
endothelin11 is widely regarded to increase injury severity by contributing to lesion 
development, BBB disruption and edema.  In mice overexpressing endothelin11, BBB 
permeability was increased, as was brain edema and lesion volume compared to wild type 
controls
33
 Also, the development of brain edema post ischemia has been shown in animal 
models to be dependent on endothelin11, which is thought to increase aquaporin4 channel 
expression on astrocytic end1feet, facilitating water uptake across the BBB.
33 
Endoglin 
(CD105) is an accessory protein of the transforming growth factor1β receptor system, is 
expressed predominantly on endothelial cells, and is increased in expression during 
angiogenesis, in which it contributes to smooth muscle and endothelial proliferation, pericyte 
migration and production of ECM proteins.
34
 Under ischemic conditions endoglin expression 
is increased on mouse endothelium, and is also found abundantly in the ischemic hemisphere 
28 days after permanent MCAo in mice.
35
 Therefore in the present study the absence of 
endoglin in the Wsh
 
mouse brain may be indicative of a less responsive vascular 
endothelium, due to a reduction of injury to the BBB. The reduced expression profile of these 
mediators was determined at 90 minutes post1onset of occlusion. Therefore mast cells may be 
involved in reinforcing and maintaining the on1going expression of these mediators following 
induction of ischemia to contribute to BBB breakdown observed at 4 hours post1tMCAo. 
The present study establishes that mast cells may promote neutrophil infiltration at 4 hours 
post1tMCAo. However given that neutrophil accumulation peaks at later points, further 
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studies are required to establish if there are differences in kinetics of recruitment of 
neutrophils after mast cell deficiency or stabilisation. In either case, these results highlight a 
potential role of mast cells in orchestrating an early neuroinflammatory response in the 
ischemic brain. Indeed, a full repertoire of immune competent cells, including neutrophils, 
has been shown to infiltrate the ischemic hemisphere in the hours and days post tMCAo, with 
the potential to be either damaging or protective.
32
 Since mast cells are resident in the brain 
and capable of responding rapidly to produce an array of chemokines and cytokines, such as 
eotaxin, IL18 (in rodents), which promote recruitment, vascular adhesion, diapadesis and 
activation of leukocytes, they may act as a beacon to initiate neuroinflammation during the 
acute ischemic period.  This concept is supported by the finding that mast cells were activated 
prior to microglia in a rat model of hypoxia1ischemia, and that cromoglycate reduced both 
microglia and astrocyte activation in the subacute and chronically injured brain through 
stabilisation of mast cells. 
18  
However since neutrophils also release MMP19 and have also 
been shown to affect BBB permeability, it is unclear in the present study whether BBB 
breakdown is caused by mediators derived from mast cells or neutrophils or both. In future 
studies Wsh mice reconstituted with BMMC from MMP19
1/1 
or WT mice can be used to 
demonstrate whether MMP19 induced BBB breakdown is mast cell1 derived. 
The reduction in recruitment of neutrophils, BBB permeability and brain edema may have 
been expected to translate to reduced lesion size. A more stable BBB should reduce exposure 
to potentially toxic circulating proteins, offering neuroprotection. Additionally, alleviation of 
edema could reduce lesion development by preventing vascular compression, secondary 
ischemia, and herniation.
36
 However, whilst mast cell stabilisation by cromoglycate reduced 
lesion development compared to vehicle, there was no significant effect on lesion size in Wsh 
compared to WT mice. This discrepancy may be either due to other known abnormalities in 
Wsh mice, albeit these would be expected to increase not decrease infarct size, or due to 
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additional non1specific contributing protective effects of cromoglycate, however this is 
unlikely given that cromoglycate did not affect lesion size in Wsh mice, indicating an effect 
specific to mast cells. Alternatively, this discrepancy possibly reflects the 4 hour ischemic 
period measured and that cromoglycate may be delaying evolution of infarct.   
Despite this it appears mast cells may be important for mortality beyond four hours of 
reperfusion.   The extent of brain edema, around a 10% increase in the ipsilateral hemisphere 
volume, was similar in WT mice after both 4 hours and 72 hours of reperfusion, and at the 
latter time point Wsh mice were affected to a similar degree.  This could indicate that brain 
edema develops at a slower rate in the absence of mast cells.  Additionally, in WT mice 
recovering to 72 hours there was 25% (2 animals) mortality within the first 24 hours, which 
was attributed to brain edema, whilst there was no mortality in the Wsh mice.  Therefore, 
mast cells may be causal to this increased mortality by mediating the development of brain 
edema in the period of reperfusion between 4 and 24 hours. 
After 72 hours of recovery the role of mast cells seems to be less important in this model 
compared to the acute recovery period.   It may be the case that after the initial BBB opening 
in the acute ischemic period that the mast cell population is exhausted from overt 
degranulation and is no longer capable of influencing the BBB.  There is some evidence to 
support this idea from studies in ischemic stroke and traumatic brain injury in rats.  After one 
day of recovery from traumatic brain injury there was a dramatic decrease in the numbers of 
mast cells in the brain compared to uninjured controls, and the population remained low at 
the fourth day of recovery.  Also, evaluation of BBB opening for 5 weeks following 90 
minutes tMCAo in rats indicated a gradual repair of the BBB after an initial surge in opening 
during the first six hours of reperfusion.  Interestingly, it took around one week for the mast 
cell population to be restored to normal levels following traumatic brain injury, whilst the 
BBB in rats who underwent tMCAo was again highly permeable after one week of 
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reperfusion.
37,38
 The alternative to this is that mast cells are essential for maintaining the 
integrity of the BBB in the period beyond the 72 hour reperfusion time point analysed.  It is 
known that mast cells are important modulators of angiogenesis,
9
 and in their absence normal 
BBB repair mechanisms may be impaired. A better understanding of the temporal profile of 
mast cell contribution to BBB opening will increase our understanding of when any mast cell 
directed intervention may be appropriate.  
The role of TNF1α in experimental stroke is not clear cut, as it has been shown to be 
protective and damaging in animal models.
19,20
 TNF receptor (TNFR) subtype appears to 
dictate whether TNF1α elicits protective or detrimental responses dependent on downstream 
adaptor proteins, with TNFR1 activation leading to cell death and TNFR2 activation 
promoting survival. However, in this model TNF1α does not appear to be responsible for 
ischemic pathology related to mast cells or otherwise as there was no detected decrease in 
TNF1α in brain homogenates following tMCAo in Wsh
 
mice compared to WT or indeed 
sham operated mice of either strain.  This was evident at both 25 minutes post1onset of 
occlusion, and also 90 minutes post1onset of occlusion. Worthy of note is that release of pre1
formed TNF1α from mast cell granules may be concentrated to specific regions of the brain in 
WT mice and any local increases in TNF1α might not be detected in the total hemispheric 
concentration, precluding any differences being detected.     
In summary, the data presented here indicates that mast cell numbers increase in localisation 
in the ischemic hemisphere in the acute period of reperfusion following tMCAo and are 
potentially initiators of neuroinflammation and BBB breakdown. The successful utilisation of 
	  models of mast cells such as Wsh mice in the present study extends their use for 
subsequent research into mechanistic insight of these cells after stroke. 
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Titles and legends to figures 
Figure 1:  Cerebral blood flow and neurological deficit were unaffected by mast cell 
deficiency.  In WT (n=6) and Wsh (n=6) mice, cerebral blood flow was measured throughout 
the occlusion period of 45 minutes by laser Doppler flowmetry (A).  General (B) and Focal 
(C) deficits were assessed on a scale from 0 (healthy) to 28 (moribund) in WT (n=6) and Wsh 
(n=6) at 24, 48 and 72 hours post 45 minute tMCAo (mean + SEM, two1way ANOVA). 
Figure 2:  Mast cell numbers increased in the ischemic hemisphere post tMCAo.  
Toluidine blue stained mast cells, found within the neuropil (A) and at perivascular locations 
(B) were counted in 24 tissues sections in WT mice at 4 hours post1tMCAo (n=8), in sham 
(n=5) and in naïve WT mice (n=3) (C). Comparisons were made between ipsilaterally versus 
contralaterally located mast cells in WT mice following tMCAo, sham and naïve (D) and 
anteriorally versus posteriorally located mast cells following tMCAo, sham and naïve (E) 
(mean + SEM, *<0.05 ipsilateral compared to contralateral side in tMCAo mice, 
#
<0.05 
posterior compared to anterior, Students unpaired t1test, IA=interaural). 
Figure 3:  Immunoglobulin G leakage into brain tissue was reduced by mast cell 
stabilisation and deficiency.  Endogenous IgG was detected by immunostaining of the level 
of the hypothalamus in WT and Wsh mice pre1treated with cromoglycate versus vehicle 
(n=6/group) (A).  In a separate series of experiments, endogenous IgG density was measured 
in Wsh versus WT mice at 4 hours (n=6/group) (B) and 72 hours (n=5 Wsh, n=6 WT) (C) 
post1tMCAo (mean + SEM, *<0.05 compared to WT vehicle, #<0.05 compared to WT, 
Students unpaired t1test, SCG= cromoglycate). 
Figure 4:  Edema volume was reduced by mast cell stabilisation and deficiency.  The 
degree of swelling of the ipsilateral hemisphere compared to the contralateral hemisphere was 
assessed in haematoxylin and eosin stained tissues sections from the MCA territory in Wsh 
and WT mice pre1treated with cromoglycate versus vehicle (n=7/group) (A).  Edema was 
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measured in WT (n=8) versus Wsh (n=7) that underwent 4 hours of reperfusion (B) and 72 
hours reperfusion (n=6 both groups) (C) (mean + SEM, *<0.05 compared to WT vehicle, 
#<0.05 compared to WT, Students unpaired t1test, SCG= cromoglycate). 
Figure 5:  Neutrophils recruitment was attenuated by mast cell stabilisation and 
deficiency.  Immunostained neutrophil numbers were quantified in duplicate tissue sections 
in WT (n= 7 SCG, n= 6 vehicle) and Wsh (n=6 per group) mice pre1treated with 
cromoglycate or vehicle at 4 hours post1tMCAo (A). In a separate study, neutrophils were 
also quantified in Wsh (n=6) and WT (n=7) after tMCAo and sham surgery (n=5/group) (B) 
(mean + SEM, *<0.01 vehicle versus cromoglycate in WT only, #<0.05 WT versus Wsh, 
Students unpaired t1test, SCG= cromoglycate). 
Figure 6:  Volume of tissue damage was decreased by mast cell stabilisation.  Ischemic 
lesion volume at 4 hours post1tMCAo was measured in haematoxylin and eosin stained tissue 
section representative of the MCA territory in WT and Wsh mice pre1treated with 
cromoglycate (WT n=7; Wsh n=6) or vehicle (WT n=7; Wsh n=6) (A). In separate series of 
experiments, lesion volume was measured in Wsh compared to WT mice at 4 hours post 
tMCAo (WT n=8, Wsh n=7) (B) and 72 hours post1tMCAo (WT n=6, Wsh n=6) (C) (mean + 
SEM, *<0.05 vehicle versus cromoglycate in WT, Students unpaired t1test, SCG= 
cromoglycate). 
Figure 7:  Angiogenesis proteome profile but not TNF2α concentration was altered by 
mast cell deficiency.  TNF1α concentration was measured by ELISA in brain homogenates at 
25 minutes post1onset of occlusion in Wsh (n=6) versus WT (n=6) mice and in sham animals 
(n=4/group) (A) and 90 minutes post1onset of occlusion in Wsh (n=6) versus WT (n=6) mice 
and in sham animals (n=4/group) (B) (mean + SEM, one1way ANOVA, n.s.) Expression of 
an array of 53 proteins related to angiogenesis was evaluated in brain homogenates in Wsh 
and WT mice at 90 minutes post1onset of occlusion, presented as representative blots (C) and 
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as % of positive control reference spot for individual experiments (D) (End= endoglin; ET11= 
endothelin11). 
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